Anaptysbio (ANAB) Other Accumulated Expenses (2016 - 2026)

Anaptysbio has reported Other Accumulated Expenses for 9 years, with the latest figure at $17.8 million in Q1 2026.

• For the quarter ending Q1 2026, Other Accumulated Expenses changed N/A year-over-year to $17.8 million; the trailing twelve-month figure through Mar 2026 stood at $17.8 million (changed N/A YoY), and the FY2025 full-year result was $16.4 million, down 45.71% from the prior year.
• Other Accumulated Expenses for Q1 2026 stood at $17.8 million, up from $16.4 million in the prior quarter.
• The five-year high for Other Accumulated Expenses was $30.2 million in Q4 2024, with the low at $16.4 million in Q4 2025.
• Historically, Other Accumulated Expenses has averaged $21.5 million across 3 years, with a median of $17.8 million in 2026.
• The largest YoY upside for Other Accumulated Expenses was 45.71% in 2025 against a maximum downside of 45.71% in 2025.
• Anaptysbio's Other Accumulated Expenses stood at $30.2 million in 2024, then slumped by 45.71% to $16.4 million in 2025, then increased by 8.47% to $17.8 million in 2026.
• The last three Other Accumulated Expenses figures came in at $17.8 million (Q1 2026), $16.4 million (Q4 2025), and $30.2 million (Q4 2024), per Business Quant data.